Literature DB >> 28062489

Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype: An Analysis of 431 239 Patients.

Patrick M Moriarty1, Stephen A Varvel1, Philip L S M Gordts1, Joseph P McConnell1, Sotirios Tsimikas2.   

Abstract

OBJECTIVE: Lipoprotein(a) [Lp(a)] levels are genetically determined by hepatocyte apolipoprotein(a) synthesis, but catabolic pathways also influence circulating levels. APOE genotypes have different affinities for the low-density lipoprotein (LDL) receptor and LDL-related protein-1, with ε2 having the weakest binding to LDL receptor at <2% relative to ε3 and ε4. APPROACH AND
RESULTS: APOE genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, and ε4/ε4), Lp(a) mass, directly measured Lp(a)-cholesterol levels, and a variety of apoB-related lipoproteins were measured in 431 239 patients. The prevalence of APOE traits were ε2: 7.35%, ε3: 77.56%, and ε4: 15.09%. Mean (SD) Lp(a) levels were 65% higher in ε4/ε4 compared with ε2/ε2 genotypes and increased significantly according to APOE genotype: ε2/ε2: 23.4 (29.2), ε2/ε3: 31.3 (38.0), ε2/ε4: 32.8 (38.5), ε3/ε3: 33.2 (39.1), ε3/ε4: 35.5 (41.6), and ε4/ε4: 38.5 (44.1) mg/dL (P<0.0001). LDL-cholesterol, apoB, Lp(a)-cholesterol, LDL-cholesterol corrected for Lp(a)-cholesterol content, LDL-particle number, and small, dense LDL also had similar patterns. Patients with LDL-cholesterol ≥250 mg/dL, who are more likely to have LDL receptor mutations and reduced affinity for apoB, had higher Lp(a) levels across all apoE isoforms, but particularly in patients with ε2 alleles, compared with LDL <250 mg/dL. The lowest Lp(a) mass levels were present in patients with ε2 isoforms and lowest LDL-cholesterol.
CONCLUSIONS: APOE genotypes strongly influence Lp(a) and apoB-related lipoprotein levels. This suggests that differences in affinity of apoE proteins for lipoprotein clearance receptors may affect Lp(a) catabolism, suggesting a competition between Lp(a) and apoE protein for similar receptors.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  alleles; cholesterol; genotype; hepatocytes; prevalence

Mesh:

Substances:

Year:  2017        PMID: 28062489      PMCID: PMC5323356          DOI: 10.1161/ATVBAHA.116.308704

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  42 in total

1.  The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings.

Authors:  Jennifer L Jenner; Leo J Seman; John S Millar; Stefania Lamon-Fava; Francine K Welty; Gregory G Dolnikowski; Santica M Marcovina; Alice H Lichtenstein; P Hugh R Barrett; Carl deLuca; Ernst J Schaefer
Journal:  Metabolism       Date:  2005-03       Impact factor: 8.694

2.  Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing.

Authors:  Robert W Mahley; Yadong Huang
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins.

Authors:  A Steinmetz; C Jakobs; S Motzny; H Kaffarnik
Journal:  Arteriosclerosis       Date:  1989 May-Jun

4.  Comparison of the LDL-receptor binding of VLDL and LDL from apoE4 and apoE3 homozygotes.

Authors:  C D Mamotte; M Sturm; J I Foo; F M van Bockxmeer; R R Taylor
Journal:  Am J Physiol       Date:  1999-03

5.  Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein.

Authors:  R C Kowal; J Herz; K H Weisgraber; R W Mahley; M S Brown; J L Goldstein
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

6.  Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans.

Authors:  Jon C Gonzales; Philip L S M Gordts; Erin M Foley; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2013-05-08       Impact factor: 14.808

7.  Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.

Authors:  Sotirios Tsimikas; Nicholas J Viney; Steven G Hughes; Walter Singleton; Mark J Graham; Brenda F Baker; Jennifer L Burkey; Qingqing Yang; Santica M Marcovina; Richard S Geary; Rosanne M Crooke; Joseph L Witztum
Journal:  Lancet       Date:  2015-07-22       Impact factor: 79.321

Review 8.  Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans.

Authors:  Mark J Graham; Nick Viney; Rosanne M Crooke; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2015-11-04       Impact factor: 5.922

9.  Receptor-mediated catabolism of low density lipoprotein in man. Quantitation using glucosylated low density lipoprotein.

Authors:  Y A Kesaniemi; J L Witztum; U P Steinbrecher
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

10.  The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans.

Authors:  D J Rader; W A Mann; W Cain; H G Kraft; D Usher; L A Zech; J M Hoeg; J Davignon; P Lupien; M Grossman
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

View more
  26 in total

1.  APOE and the Association of Fatty Acids With the Risk of Stroke, Coronary Heart Disease, and Mortality.

Authors:  Claudia L Satizabal; Cécilia Samieri; Kendra L Davis-Plourde; Barbara Voetsch; Hugo J Aparicio; Matthew P Pase; José Rafael Romero; Catherine Helmer; Ramachandran S Vasan; Carlos S Kase; Stéphanie Debette; Alexa S Beiser; Sudha Seshadri
Journal:  Stroke       Date:  2018-12       Impact factor: 7.914

Review 2.  Apolipoprotein E and Atherosclerosis.

Authors:  A D Marais
Journal:  Curr Atheroscler Rep       Date:  2021-05-10       Impact factor: 5.113

Review 3.  Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Authors:  Shipra Agrawal; Joshua J Zaritsky; Alessia Fornoni; William E Smoyer
Journal:  Nat Rev Nephrol       Date:  2017-11-27       Impact factor: 28.314

4.  Highlighting Residual Atherosclerotic Cardiovascular Disease Risk.

Authors:  Yunosuke Matsuura; Jenny E Kanter; Karin E Bornfeldt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

Review 5.  Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?

Authors:  Željko Reiner
Journal:  Curr Atheroscler Rep       Date:  2019-03-07       Impact factor: 5.113

6.  Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.

Authors:  Aurélie Thedrez; Dirk J Blom; Stéphane Ramin-Mangata; Valentin Blanchard; Mikaël Croyal; Kévin Chemello; Brice Nativel; Matthieu Pichelin; Bertrand Cariou; Steeve Bourane; Lihua Tang; Michel Farnier; Frederick J Raal; Gilles Lambert
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-12-28       Impact factor: 8.311

Review 7.  NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.

Authors:  Sotirios Tsimikas; Sergio Fazio; Keith C Ferdinand; Henry N Ginsberg; Marlys L Koschinsky; Santica M Marcovina; Patrick M Moriarty; Daniel J Rader; Alan T Remaley; Gissette Reyes-Soffer; Raul D Santos; George Thanassoulis; Joseph L Witztum; Simhan Danthi; Michelle Olive; Lijuan Liu
Journal:  J Am Coll Cardiol       Date:  2018-01-16       Impact factor: 24.094

8.  Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: a pilot study.

Authors:  Valentin Blanchard; Stéphane Ramin-Mangata; Stéphanie Billon-Crossouard; Audrey Aguesse; Manon Durand; Kevin Chemello; Brice Nativel; Laurent Flet; Maud Chétiveaux; David Jacobi; Jean-Marie Bard; Khadija Ouguerram; Gilles Lambert; Michel Krempf; Mikaël Croyal
Journal:  J Lipid Res       Date:  2018-03-14       Impact factor: 5.922

9.  Lipoprotein(a): the common, likely causal, yet elusive risk factor for cardiovascular disease.

Authors:  Pia R Kamstrup
Journal:  J Lipid Res       Date:  2017-07-11       Impact factor: 5.922

10.  Association of vitamins, minerals, and lead with Lipoprotein(a) in a cross-sectional cohort of US adults.

Authors:  Eric J Brandt; Daniel J Brandt; Nihar R Desai; Erica S Spatz; Khurram Nasir; Arya Mani
Journal:  Int J Vitam Nutr Res       Date:  2021-05-24       Impact factor: 1.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.